Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge.
Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge.
复制标题
DOI：
10.1016/j.vaccine.2007.10.063
复制
发表时间：
2008-01-24
期刊：
影响因子：
5.5
通讯作者：
Monath, Thomas P.
中科院分区：
文献类型：
--
作者：
Marriott, Kathleen A.;Parkinson, Christopher V.;Morefield, Samantha I.;Davenport, Robert;Nichols, Richard;Monath, Thomas P.
天花作为一种生物恐怖主义制剂的潜在用途重新引起了人们对开发能够取代标准Dryvax®疫苗的现代疫苗的兴趣。在非人灵长类动物模型中测试从Dryvax®克隆分离并在细胞培养物中制造的牛痘病毒（ACAM 2000）的免疫原性和保护活性。接种ACAM 2000、Dryvax®或ACAM 2000稀释剂（对照）的食蟹猴在接种后2个月用致死剂量的猴痘病毒进行攻毒。ACAM 2000证明免疫原性和有效的保护免受致命的猴痘攻击，从缺乏攻击后病毒复制，以及没有任何显著的临床症状可归因于猴痘感染。这种保护与相当于Dryvax®组疫苗接种后产生的中和抗体滴度以及攻击后中和抗体存在的类似显著增加相关。对照动物未显示疫苗诱导的血清转化迹象，显示攻毒后组织相关病毒复制和病毒血症，并出现严重的猴痘特异性临床症状。研究发现，ACAM 2000的保护效力与目前批准的疫苗Dryvax®相当。
The potential use of smallpox as an agent of bioterrorism has renewed interest in the development of a modern vaccine capable of replacing the standard Dryvax® vaccine. Vaccinia virus (ACAM2000), clonally isolated from Dryvax® and manufactured in cell culture, was tested for immunogenicity and protective activity in a non-human primate model. Cynomolgus monkeys vaccinated with ACAM2000, Dryvax®, or ACAM2000 diluent (control) were challenged 2 months post-vaccination with a lethal, intravenous dose of monkeypox virus. ACAM2000 proved immunogenic and efficacious in protecting against lethal monkeypox challenge, as evident from a lack of post-challenge viral replication, and the absence of any significant clinical signs attributable to monkeypox infection. This protection correlated (with) neutralizing antibody titers equivalent to those generated in the Dryvax® group post-vaccination, as well as a similar significant increase in the presence of neutralizing antibodies post-challenge. Control animals showed no signs of vaccine-induced seroconversion, displayed post-challenge tissue-associated viral replication and viremia, and developed severe monkeypox-specific clinical symptoms. The protective efficacy of ACAM2000 was found to be equivalent to the currently approved vaccine, Dryvax®.
登录
查看更多内容
影响因子：
5.5
作者：
Kutinova, L;Ludvikova, V;Vonka, V
通讯作者：
Vonka, V
影响因子：
82.9
作者：
Weltzin, R;Liu, J;Monath, TP
通讯作者：
Monath, TP
影响因子：
6.4
作者：
McClain, DJ;Harrison, S;Graham, JA
通讯作者：
Graham, JA
影响因子：
5.4
作者：
Hooper, JW;Thompson, E;Jahrling, PB
通讯作者：
Jahrling, PB
影响因子：
64.8
作者：
Earl, PL;Americo, JL;Moss, B
通讯作者：
Moss, B